1.67
-0.07 (-3.76%)
| Previous Close | 1.73 |
| Open | 1.70 |
| Volume | 34,830 |
| Avg. Volume (3M) | 396,253 |
| Market Cap | 45,962,156 |
| Price / Sales | 0.460 |
| Price / Book | 2.22 |
| 52 Weeks Range | |
| Earnings Date | 31 Mar 2025 - 7 Apr 2025 |
| Profit Margin | -59.52% |
| Operating Margin (TTM) | -151.04% |
| Diluted EPS (TTM) | -2.96 |
| Quarterly Revenue Growth (YOY) | -7.10% |
| Current Ratio (MRQ) | 1.23 |
| Operating Cash Flow (TTM) | -102.22 M |
| Levered Free Cash Flow (TTM) | -56.57 M |
| Return on Assets (TTM) | -38.05% |
| Return on Equity (TTM) | -1,739.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Fortress Biotech, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.25 |
|
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 27.70% |
| % Held by Institutions | 17.36% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Pvg Asset Management Corp | 31 Dec 2024 | 386,295 |
| Envestnet Asset Management Inc | 31 Dec 2024 | 239,594 |
| Kestra Advisory Services, Llc | 31 Dec 2024 | 226,231 |
| Hb Wealth Management, Llc | 31 Dec 2024 | 106,850 |
| 52 Weeks Range | ||
| Median | 16.00 (860.96%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Roth MKM | 11 Mar 2025 | 16.00 (860.96%) | Buy | 1.73 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |